- PureTech Health said it had acquired a clinical-stage product candidate for the potential treatment of lymphatic and immunofibrotic diseases, including lymphedema.

In preclinical studies, the oral, small molecule candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms, the company said.

Additionally, in a Phase 1 clinical trial in healthy volunteers, LYT-100 was observed to be well tolerated with a favourable pharmacokinetic profile to support twice daily oral dosing.

The company said LYT-100 expanded its internal R&D pipeline and continued its progress in developing new medicines based on insights into the lymphatic system and local modulation of the immune system for the treatment of immune and central nervous system disorders, lymphatic conditions, and cancers.

At 8:23am: [LON:PRTC] PureTech Health Plc share price was -6p at 246p

Story provided by